Spotify Discloses Royalties, COMCE's Investment Plans: Tech Week

Spotify paid over US$9 billion in royalties globally in 2023, with US$317 million directed to Mexican artists, addressing previous criticisms regarding transparency. Meanwhile, COMCE unveiled strategies to enhance Mexico's appeal as an investment hub, focusing on innovation and sustainability. In industry trends, Zeus Talent showcased that HR software can elevate business productivity by over 20%, and CleverTap's market report emphasized that AI adoption could quadruple conversion rates for brands. 

Internationally, the European Commission launched an investigation into Meta over child safety concerns, while the FDA cleared Neuralink for a second brain chip implant despite past issues, with plans for trials in Canada and the United Kingdom.

This is the Week in Tech!

Mexico

Spotify 2023 Royalty Payments in Mexico Reach US$300 Million

In response to criticism for lack of transparency regarding royalty management, Spotify, the global leader in music streaming, through its Loud&Clear annual earnings report, announced that in 2023, it paid more than US$9 billion in royalties globally, with more than MX$5.3 billion (US$317 million) going to Mexican artists.

COMCE Boosts Mexico as a Foreign Investment Destination

The Mexican Business Council for Foreign Trade, Investment and Technology (COMCE) has presented a strategy to strengthen Mexico's position as an investment destination. Through various initiatives, this approach aims to attract innovative projects that drive technological advancement and sustainability, as well as strengthen the national value chain. 

Industry Trends

HR Software Increases Business Productivity by Over 20% 

 Zeus Talent, a company focused on human capital management (HCM) solutions in Mexico, has announced that its software can increase the productivity of companies by more than 20%. These findings are based on internal studies and analysis carried out by the company and its Founder and CEO, Guillermo Simonini.

Gender Gap in Mobile Internet Usage Narrows

The Global System of Mobile Communications Association’s (GSMA) recent Mobile Gender Gap Report 2024 revealed that in 2023, the gender gap in mobile Internet use narrowed for the first time since the COVID-19 pandemic, marking a significant development in the race for digital equity. According to the study, women are adopting mobile Internet at a faster rate than men in low- and middle-income countries. However, significant structural challenges remain that require a concerted multi-stakeholder response to ensure true equity in access to and use of digital technologies.

AI Adoption Can Quadruple Conversion Rates: CleverTap

Brands that incorporate artificial intelligence (AI) into their processes see a four-fold increase in conversion rates, potentially boosting business value and ROI, according to CleverTap’s 2024 market research report titled "The AI Advantage in Customer Acquisition."

The report highlights that inefficient AI adoption can result in brands missing out on up to four times more conversions and greater business value. CleverTap assessed the impact of its AI engine, Clever.AI, and categorized brands into three levels based on their AI-driven customer acquisition use cases.

International

EU Investigates Meta Over Child Safety

The European Commission has formally launched an investigation into Meta, the parent company of Facebook and Instagram, citing concerns regarding the platforms' potential to induce addictive behaviors among children and negatively impact their mental health. This investigation marks a significant enforcement action under the Digital Services Act (DSA), which mandates stringent online safety measures, particularly for protecting minors.

FDA Clears Neuralink's Brain Chip Implant for Second Patient

The US Food and Drug Administration (FDA) has approved Neuralink for a second brain chip implantation, despite the partial detachment of the device in the first patient. The new implant will embed wires deeper to prevent this problem. Neuralink is also seeking clinical trial  approval for similar trials in Canada and the United Kingdom.